Thanks to an investment from 819 Evergreen Fund I, we are pleased to be able to continue working on our ambitions: cure cancer patients by making Natural Killer cells a reality. Our activities will be realized in Maastricht.

CiMaas is transforming cancer treatment by developing innovative immunotherapies that harness the body’s immune system to address unmet needs in metastatic and late-stage cancers. Current therapies cure only 60% of patients in the Western world and often fail in advanced cases.

CiMaas focuses on safe, effective solutions that minimize side effects while enhancing quality of life. By integrating multiple components of the immune system, CiMaas aims to deliver more robust, lasting treatments—bringing new hope to patients.

For collaborations with partners, (non-) GMP-grade feeder cells are now also available. These make it possible to let Natural Killer expand sufficiently, so that large numbers of these cells can be produced for both scientific research and treatment of patients. Furthermore, we aim to have clinical production ready for Natural Killer cells soon to start clinical research in collaboration with various partners.

 ,